Perhexiline

Generic Name
Perhexiline
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H35N
CAS Number
6621-47-2
Unique Ingredient Identifier
KU65374X44
Background

Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.

Indication

For the management of severe angina pectoris.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Role of Perhexiline in Hypertrophic Cardiomyopathy

First Posted Date
2020-06-11
Last Posted Date
2021-03-11
Lead Sponsor
Flinders University
Target Recruit Count
60
Registration Number
NCT04426578
Locations
🇦🇺

Flinders Medical Centre, Adelaide, South Australia, Australia

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

First Posted Date
2016-08-11
Last Posted Date
2017-08-31
Lead Sponsor
Heart Metabolics Limited
Target Recruit Count
35
Registration Number
NCT02862600
Locations
🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure

Phase 3
Withdrawn
Conditions
Hypertrophic Cardiomyopathy
Interventions
Drug: Placebo
Drug: Perhexiline
First Posted Date
2015-04-30
Last Posted Date
2017-07-14
Lead Sponsor
Heart Metabolics Limited
Registration Number
NCT02431221

Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy

First Posted Date
2009-10-05
Last Posted Date
2011-08-11
Lead Sponsor
University Hospital Birmingham
Target Recruit Count
220
Registration Number
NCT00989508
Locations
🇬🇧

University Hospital Birmingham, Birmingham, West Midlands, United Kingdom

Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery

First Posted Date
2009-02-18
Last Posted Date
2010-05-20
Lead Sponsor
University Hospital Birmingham
Target Recruit Count
290
Registration Number
NCT00845364
Locations
🇬🇧

Brighton & Sussex University Hospitals NHS Trust, Brighton, West Sussex, United Kingdom

🇬🇧

University Hospital Birmingham, Birmingham, West Midlands, United Kingdom

Metabolic Manipulation in Chronic Heart Failure

Phase 2
Completed
Conditions
Chronic Heart Failure
Interventions
Drug: Placebo
Drug: Perhexiline
First Posted Date
2009-02-11
Last Posted Date
2011-11-29
Lead Sponsor
University Hospital Birmingham NHS Foundation Trust
Target Recruit Count
50
Registration Number
NCT00841139
Locations
🇬🇧

University Hospitals Brimingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom

🇬🇧

University of Birmingham, Birmingham, West Midlands, United Kingdom

Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome

Phase 2
Completed
Conditions
Diastolic Heart Failure
Interventions
Drug: Placebo
Drug: Perhexiline
First Posted Date
2009-02-09
Last Posted Date
2015-11-05
Lead Sponsor
University of Aberdeen
Target Recruit Count
70
Registration Number
NCT00839228
Locations
🇬🇧

University of Aberdeen, Aberdeen, United Kingdom

Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes

Phase 1
Conditions
Diabetic Cardiomyopathy
Interventions
Drug: Perhexiline
First Posted Date
2008-03-04
Last Posted Date
2008-03-04
Lead Sponsor
University Hospital Birmingham
Target Recruit Count
75
Registration Number
NCT00628056
Locations
🇬🇧

University of Birmingham, Birmingham, Westmidlands, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy